Pictet Asset Management Holding SA Acquires 542,361 Shares of Taysha Gene Therapies, Inc. $TSHA

Pictet Asset Management Holding SA lifted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 19.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,313,062 shares of the company’s stock after purchasing an additional 542,361 shares during the period. Pictet Asset Management Holding SA owned 1.02% of Taysha Gene Therapies worth $16,135,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Privium Fund Management B.V. boosted its stake in Taysha Gene Therapies by 17.1% during the 3rd quarter. Privium Fund Management B.V. now owns 232,900 shares of the company’s stock valued at $1,134,000 after purchasing an additional 34,000 shares during the period. Alps Advisors Inc. increased its position in Taysha Gene Therapies by 48.6% in the 3rd quarter. Alps Advisors Inc. now owns 431,669 shares of the company’s stock worth $2,102,000 after buying an additional 141,126 shares during the period. Chicago Partners Investment Group LLC increased its position in Taysha Gene Therapies by 1.8% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 226,379 shares of the company’s stock worth $896,000 after buying an additional 4,032 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Taysha Gene Therapies in the 3rd quarter worth approximately $81,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Taysha Gene Therapies by 9.8% during the third quarter. ProShare Advisors LLC now owns 44,800 shares of the company’s stock worth $218,000 after buying an additional 3,983 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on TSHA. Wolfe Research assumed coverage on Taysha Gene Therapies in a research report on Thursday, September 17th. They issued an “outperform” rating for the company. The Goldman Sachs Group boosted their target price on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, September 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $12.77.

Taysha Gene Therapies Price Performance

Shares of TSHA stock opened at $4.21 on Friday. The stock has a 50 day moving average of $4.52 and a two-hundred day moving average of $5.28. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13. Taysha Gene Therapies, Inc. has a 12 month low of $3.45 and a 12 month high of $7.30. The company has a market capitalization of $1.37 billion, a P/E ratio of -10.02 and a beta of 1.36.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.03. As a group, equities analysts expect that Taysha Gene Therapies, Inc. will post -0.52 EPS for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for rare, genetically driven diseases. Based in Dallas, Texas, the company was founded in 2019 and has built its programs around adeno-associated virus delivery technology. The company’s lead program, TSHA-102, is an investigational gene therapy being developed for Rett syndrome, a rare neurological disorder. Taysha’s research has also included gene therapy programs for other rare diseases, including giant axonal neuropathy.